New! Sign up for our free email newsletter.
Science News
from research organizations

Lymphoma Drug Used To Treat Skin Disorders

Date:
December 17, 2007
Source:
Blackwell Publishing Ltd.
Summary:
Rituximab, a drug used to treat lymphoma, is now becoming used by dermatologists to treat various dangerous skin diseases. Originally developed as the standard therapy in treating aggressive lymphomas, the drug rituximab is showing increased non-cancer use.
Share:
FULL STORY

A new review article from the journal Dermatologic Therapy reveals that rituximab, a drug used to treat lymphoma, is now becoming used by dermatologists to treat various dangerous skin diseases.

Originally developed as the standard therapy in treating aggressive lymphomas, the drug rituximab is showing increased non-cancer use.

The study reviewed the off-label uses of rituximab in dermatology and found that it successfully treated patients with various kinds of blistering skin disease, including pemphigus vulgaris, dermatomyositis, and paraneoplastic pemphigus.

Newer, safer treatments are being studied for serious dermatologic disorders, and rituximab’s efficacy has been shown in a variety of dangerous skin problems.

“As case reports and randomized trials explore the utility of rituximab,” the authors note, “the indications for rituximab will continue to be defined.”


Story Source:

Materials provided by Blackwell Publishing Ltd.. Note: Content may be edited for style and length.


Cite This Page:

Blackwell Publishing Ltd.. "Lymphoma Drug Used To Treat Skin Disorders." ScienceDaily. ScienceDaily, 17 December 2007. <www.sciencedaily.com/releases/2007/12/071214183424.htm>.
Blackwell Publishing Ltd.. (2007, December 17). Lymphoma Drug Used To Treat Skin Disorders. ScienceDaily. Retrieved November 21, 2024 from www.sciencedaily.com/releases/2007/12/071214183424.htm
Blackwell Publishing Ltd.. "Lymphoma Drug Used To Treat Skin Disorders." ScienceDaily. www.sciencedaily.com/releases/2007/12/071214183424.htm (accessed November 21, 2024).

Explore More

from ScienceDaily

RELATED STORIES